Abstract CT101: Final results of the first-in-human study of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in patients with advanced solid tumorsNatalie Cook, Ruth Plummer, Simon A. Woodcock et al.|Cancer Research|2024Cited by 3